BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
World's top technology exhibition CES 2021
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Business > article

Biosimilar company Celltrion allowed to conduct last-stage clinical trials for Remsima SC

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : April 1, 2019, 12:34 | Updated : April 8, 2019, 16:17
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Celltrion]


SEOUL -- U.S. regulators have allowed South Korea's top biosimilar firm Celltrion to conduct only the last stage of clinical trials for Remsima SC, the subcutaneous injection of Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease.

Celltrion said Monday that Remsima SC has applied for the U.S. Food and Drug Administration's investigational new drug (IND). The company, which was allowed to skip phase 1 and 2 trials, plans to win FDA approval in 2022 after completing clinical trials for patients with inflammatory bowel disease in the U.S.

In December last year, Remsima SC applied for approval by the European Medicines Agency. Instead of an intravenous injection that takes more than two hours in hospital, patients can inject Remsima SC into the fat layer beneath the skin at home to enhance patient convenience and access to medical care.

Celltrion's biosimilars include Herzuma, based on Herceptin developed by Genentech, a subsidiary of Swiss pharmaceutical giant Roche. Truxima, the first biosimilar to Rituxan (rituximab), treats patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.

Celltrion Chairman Seo Jung-jin has unveiled an ambitious project to nurture his company as one of the world's three major biotech firms through active expansion. The company plans to set up a joint venture deal with Tasly, a Chinese pharmaceutical company, in the first half of this year.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .GC Pharmas plasma treatment allowed for actual use in treating COVID-19 patients.
    GC Pharma's plasma treatment allowed for actual use in treat…
  • .Celltrion leaves door open for consignment production of COVID-19 vaccines.
    Celltrion leaves door open for consignment production of COV…
  • . Celltrion revises deal with U.S. client to ship new rapid COVID-19 antigen test kit.
    Celltrion revises deal with U.S. client to ship new rapid C…
  • .Celltrion makes preparations for emergency domestic use of COVID-19 antibodies.
    Celltrion makes preparations for emergency domestic use of C…

Real Time Photo News

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

  • .Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series Criminal Justice.

    Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series 'Criminal Justice'

  • .CJ ENM partners with NCSoft to roll out new digital content for global market.

    CJ ENM partners with NCSoft to roll out new digital content for global market

Latest News

more+

  • Singer IU drops teaser image for upcoming full album
  • Hyundai to complete construction of fuel cell production plant in China in 2022
  • Seoul builds solar power plant on idle land near urban expressway
  • Samsung showcases new Galaxy S21 smartphone models
  • Southern city launches joint research project to develop heavy-duty flying taxi drone
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view